AIM: Profiling the efficacy and pharmacodynamic activity of the kinesin spindle protein (KSP) inhibitor ARRY-520 will aid the identification of responsive tumor types and pharmacodynamic profiles that correlate with activity. MATERIALS AND METHODS: In vivo activity was evaluated in a diverse panel of 16 different tumor xenograft models. Pharmacodynamic activity was evaluated in selected models. RESULTS: ARRY-520 had low nanomolar antiproliferative activity in tumor cell lines. Monopolar spindles were formed at active potencies. Partial or complete responses were observed in 13/16 xenograft models. Hematological tumors were particularly sensitive, with a 100% complete response rate in some models. Maintenance of mitotic block for a sufficient length of time for cells to lose survival signals and progress to apoptosis was a key component of the mechanism of activity. ARRY-520 was also active in several taxane resistant models. CONCLUSION: The data provide a rationale for clinical evaluation of the activity of ARRY-520 in hematological carcinomas and taxane-resistant tumors.
AIM: Profiling the efficacy and pharmacodynamic activity of the kinesin spindle protein (KSP) inhibitor ARRY-520 will aid the identification of responsive tumor types and pharmacodynamic profiles that correlate with activity. MATERIALS AND METHODS: In vivo activity was evaluated in a diverse panel of 16 different tumor xenograft models. Pharmacodynamic activity was evaluated in selected models. RESULTS: ARRY-520 had low nanomolar antiproliferative activity in tumor cell lines. Monopolar spindles were formed at active potencies. Partial or complete responses were observed in 13/16 xenograft models. Hematological tumors were particularly sensitive, with a 100% complete response rate in some models. Maintenance of mitotic block for a sufficient length of time for cells to lose survival signals and progress to apoptosis was a key component of the mechanism of activity. ARRY-520 was also active in several taxane resistant models. CONCLUSION: The data provide a rationale for clinical evaluation of the activity of ARRY-520 in hematological carcinomas and taxane-resistant tumors.
Authors: Warefta Hasan; Kevin Chu; Anuradha Gullapalli; Stuart S Dunn; Elizabeth M Enlow; J Christopher Luft; Shaomin Tian; Mary E Napier; Patrick D Pohlhaus; Jason P Rolland; Joseph M DeSimone Journal: Nano Lett Date: 2011-12-21 Impact factor: 11.189
Authors: Shrikanta Chattopadhyay; Alison L Stewart; Siddhartha Mukherjee; Cherrie Huang; Kimberly A Hartwell; Peter G Miller; Radhika Subramanian; Leigh C Carmody; Rushdia Z Yusuf; David B Sykes; Joshiawa Paulk; Amedeo Vetere; Sonia Vallet; Loredana Santo; Diana D Cirstea; Teru Hideshima; Vlado Dančík; Max M Majireck; Mahmud M Hussain; Shambhavi Singh; Ryan Quiroz; Jonathan Iaconelli; Rakesh Karmacharya; Nicola J Tolliday; Paul A Clemons; Malcolm A S Moore; Andrew M Stern; Alykhan F Shamji; Benjamin L Ebert; Todd R Golub; Noopur S Raje; David T Scadden; Stuart L Schreiber Journal: Cell Rep Date: 2015-02-05 Impact factor: 9.423
Authors: Patricia M LoRusso; Priscila H Goncalves; Lindsay Casetta; Judith A Carter; Kevin Litwiler; Dale Roseberry; Selena Rush; Jennifer Schreiber; Heidi M Simmons; Mieke Ptaszynski; Edward A Sausville Journal: Invest New Drugs Date: 2015-02-17 Impact factor: 3.850
Authors: Jatin J Shah; Jonathan L Kaufman; Jeffrey A Zonder; Adam D Cohen; William I Bensinger; Brandi W Hilder; Selena A Rush; Duncan H Walker; Brian J Tunquist; Kevin S Litwiler; Mieke Ptaszynski; Robert Z Orlowski; Sagar Lonial Journal: Cancer Date: 2017-08-17 Impact factor: 6.860
Authors: Robert Jones; Jacqueline Vuky; Tony Elliott; Graham Mead; José Angel Arranz; John Chester; Simon Chowdhury; Arkadiusz Z Dudek; Volker Müller-Mattheis; Marc-Oliver Grimm; Jürgen E Gschwend; Christian Wülfing; Peter Albers; Jianguo Li; Anna Osmukhina; Jeffrey Skolnik; Gary Hudes Journal: Invest New Drugs Date: 2013-01-18 Impact factor: 3.850